Substantial proportions reported they would never discuss stopping HER2 directed treatment for metastatic breast cancer (44%) or a tyrosine-kinase inhibitor for oncogene-addicted lung cancer (69%) (Table 4). Here, ERBB2 is linked to lung cancer.